Future of Biogen's Aduhelm hinges on U.S. Medicare Alzheimer's coverage
By Deena Beasley (Reuters) - The future of Aduhelm, Biogen Inc's controversial and expensive Alzheimer's drug, may hinge on a decision due this week f...
Stay updated with breaking news from James Chambers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
By Deena Beasley (Reuters) - The future of Aduhelm, Biogen Inc's controversial and expensive Alzheimer's drug, may hinge on a decision due this week f...
The future of Aduhelm, Biogen Inc's controversial and expensive Alzheimer's drug, may hinge on a decision due this week from the U.S. Medicare program on whether it will pay for the treatment.... | January 11, 2022
By Deena Beasley
By Deena Beasley (Reuters) - The future of Aduhelm, Biogen Inc's controversial and expensive Alzheimer's drug, may hinge on a decision due this week f...
Medicare took a highly unusual step to restrict access to the controversial, pricey Alzheimer’s drug Aduhelm.